Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DJI136 · LB2102

Cell therapy (CAR-T) · Kills target cells, directed at DLL3 · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer
1 Registered trials

What is DJI136?

DJI136 is an autologous T-lymphocyte preparation genetically engineered to express a chimeric antigen receptor specific for DLL3, a Notch pathway protein overexpressed on various cancer cells. The CAR-T cells recognize and selectively kill DLL3-expressing tumor cells. It is being studied in extensive-stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LB2102
Drug type
Cell therapy (CAR-T)
Targets
DLL3 (antigen)
Mechanism
Kills target cells, directed at DLL3
Pathways
Notch signaling
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
Also in trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05680922 Phase 1 Small Cell Lung Cancer Extensive Stage Active not recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung Cancer Extensive Stage

Other drugs acting on DLL3

More from Novartis Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind DJI136

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.